Gland Pharma This autumn Outcomes: Pharma firm Gland Pharma on Tuesday, Could 20, posted a weak set of numbers for the fourth quarter of the monetary 12 months 2024-25 (This autumn FY25), recording a single-digit fall within the consolidated income and revenue after tax (PAT).
Gland Pharma’s PAT got here in at ₹187 crore for the quarter below evaluate, as in opposition to ₹192 crore within the year-ago quarter, recording a 3% decline on a year-on-year foundation. In the meantime, the income from operations declined by 7% YoY to ₹1,425 crore in This autumn FY25, from ₹1,538 crore in This autumn FY24.
On the working entrance, the earnings earlier than curiosity, tax, depreciation and amortisation (EBITDA) additionally fell 3% YoY to ₹348 crore from ₹359 crore. The EBITDA margin noticed a small uptick to 24% within the March 2024 quarter from 23% within the year-ago interval.
On a sequential foundation, Gland Pharma’s income rose 3% whereas PAT was larger by 9%.
Shyamakant Giri, Chief Government Officer of Gland Pharma, commenting on the outcomes, stated, “In This autumn FY25, our consolidated income reached INR 14,249 million, with a wholesome EBITDA margin of 24%. On the bottom enterprise, the EBITDA margin expanded to 38%, pushed by quantity traction in our U.S. portfolio and high-margin new product launches. Cenexi posted modest sequential enchancment in income and gross margin, and we stay firmly dedicated to its turnaround.”
Going forward, Giri stated the strategic focus could be on accelerating progress in RoW and India, deepening U.S. presence by means of portfolio enhancement, and persevering with to guide on high quality and value effectivity.
Through the quarter, the corporate spent ₹50.3 crore on analysis and growth (R&D), representing 4.9% of income, whereas for FY25, it was ₹1,922 million (4.7% of income).
In This autumn FY25, Gland Pharma filed 5 ANDAs and 7 acquired accepted, with a complete of 24 ANDAs filed and 32 ANDAs accepted in FY25, contributing to a cumulative whole of 371 ANDA filings within the U.S. (318 accepted, 53 pending).
Gland Pharma dividend
Gland Pharma additionally advisable a remaining dividend of ₹18 or 1800% per fairness share of ₹1/- every for the monetary 12 months 2024-25.
The dividend, upon approval by the shareholders, shall be paid inside 30 days from the date of the forty seventh Annual Normal Assembly (AGM), the corporate stated.
Moreover, Gland Pharma additionally introduced the dividend file date. “The file date for the aim of figuring out the members eligible to obtain the ultimate dividend for the monetary 12 months ended March 31, 2025, is Thursday, August 14, 2025,” it stated.
Disclaimer: This story is for academic functions solely. The views and suggestions made above are these of particular person analysts or broking corporations, and never of Mint. We advise traders to verify with licensed consultants earlier than making any funding selections.
